Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis.
AUTOR(ES)
Van Gerwen, F
RESUMO
In a double-blind double-placebo crossover study naproxen (500-750 mg daily) was found to be equivalent to phenylbutazone (400-600 mg daily) in the control of disease activity in 20 patients suffering from ankylosing spondylitis during a two times 5-week trial period. No serious side effects were observed during the trial period. Gastric complaints occurred twice as often under phenylbutazone as under naproxen.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1000198Documentos Relacionados
- Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis.
- Naproxen in osteoarthrosis. Double-blind crossover trial.
- Penotrane in blepharitis. A double-blind controlled trial.
- Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy.
- Azathioprine: a controlled, double-blind trial in rheumatoid arthritis.
